scholarly journals BRCA2 Mutation Carrier

2020 ◽  
Author(s):  
Keyword(s):  
Mutation Carrier ◽  
Brca2 Mutation ◽  
Brca2 Mutation Carrier

Clinical factors used to support prophylactic mastectomy for a male BRCA2 mutation carrier

Surgery ◽  
2006 ◽  
Vol 139 (5) ◽  
pp. 704-706 ◽  
Author(s):  
Maryam Guiahi ◽  
Sheryl G.A. Gabram ◽  
Kathy S. Albain ◽  
Pauline Camacho ◽  
Bhuma Krishnamachari ◽  
...  
Keyword(s):  
Mutation Carrier ◽  
Prophylactic Mastectomy ◽  
Brca2 Mutation ◽  
Clinical Factors ◽  
Brca2 Mutation Carrier

scholarly journals Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer

2017 ◽  
Vol 10 (2) ◽  
pp. 433-437 ◽  
Author(s):  
María Jesús  Rubio Pérez
Keyword(s):  
Ovarian Cancer ◽  
Mutation Carrier ◽  
Liposomal Doxorubicin ◽  
Brca2 Mutation ◽  
Pegylated Liposomal Doxorubicin ◽  
Second Line ◽  
Brca2 Mutation Carrier ◽  
Second Line Chemotherapy ◽  
Platinum Sensitive ◽  
Line Chemotherapy

Introduction: The current standard of care for ovarian cancer is optimal cytoreduction with adjuvant chemotherapy based on a platinum/taxane combination. Although the response rate to this therapy is high, most patients ultimately relapse. Response to second-line therapy and prognosis are linked to the platinum-free interval (PFI); when both improve, the PFI increases. As a result, there is an increasing interest in the PFI extension strategies including platinum-free combinations. Case Presentation: A 50-year-old postmenopausal woman presented with ovarian serous carcinoma with peritoneal carcinomatosis. First-line neoadjuvant chemotherapy with carboplatin plus paclitaxel was initiated, followed by surgery and carboplatin plus paclitaxel chemotherapy. Eight months after the last cycle, CT revealed extensive supra- and infradiaphragmatic node involvement, and second-line chemotherapy was initiated with trabectedin and pegylated liposomal doxorubicin (PLD). Partial response was achieved and successfully maintained for 18 cycles. After the 18th cycle and a 25-month PFI, CT imaging evidenced disease progression. As the patient was a BRCA2 mutation carrier, third-line chemotherapy was initiated with carboplatin and gemcitabine every 3 weeks. After the third cycle, imaging confirmed complete response, which was maintained after the sixth and final cycle. Maintenance treatment with olaparib was initiated. At present – 6 months after the start of maintenance chemotherapy with olaparib – the patient is disease free. Conclusions: Second-line chemotherapy with a nonplatinum combination – trabectedin plus PLD – was effective in a BRCA2 mutation carrier with recurrent partially platinum-sensitive ovarian cancer.

Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer

2009 ◽  
Vol 6 (10) ◽  
pp. 604-607 ◽  
Author(s):  
Seema Panchal ◽  
Orli Shachar ◽  
Frances O'Malley ◽  
Pavel Crystal ◽  
Jaime Escallon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Mutation Carrier ◽  
Brca2 Mutation ◽  
Brca2 Mutation Carrier ◽  
History Of

Combining risk-reducing salpingo-oophorectomy with mastectomy and reconstructive surgery in BRCA1 and BRCA2 mutation carrier

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 1532-1532
Author(s):  
L. Chen ◽  
B. Crawford ◽  
J. McLennan ◽  
E. S. Hwang ◽  
R. Foster ◽  
...  
Keyword(s):  
Reconstructive Surgery ◽  
Mutation Carrier ◽  
Brca2 Mutation ◽  
Brca2 Mutation Carrier ◽  
Brca1 And Brca2 ◽  
Risk Reducing
Sign in / Sign up

Export Citation Format

Share Document